Last reviewed · How we verify
18F-DCFPyL
At a glance
| Generic name | 18F-DCFPyL |
|---|---|
| Also known as | PyL, [F18]-Piflufolastat, Pylarify, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}ureido)-pentanedioic acid, 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, 10.0 A bolus of less than or equal to 9 mCi (331 MBq) of 18F-DCFPyL will be injected into the IV line by slow push IV push. |
| Sponsor | Progenics Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy (PHASE2)
- Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
- Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor (PHASE2)
- PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer (PHASE3)
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PHASE2)
- PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
- Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT (EARLY_PHASE1)
- Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-DCFPyL CI brief — competitive landscape report
- 18F-DCFPyL updates RSS · CI watch RSS
- Progenics Pharmaceuticals, Inc. portfolio CI